Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Secondary analyses

TK Tero Kortekangas
RL Ristomatti Lehtola
HL Hannu-Ville Leskelä
ST Simo Taimela
PO Pasi Ohtonen
OS Olli Savola
TJ Teppo Järvinen
HP Harri Pakarinen
ask Ask a question
Favorite

We will quantify the treatment effect on an intention to treat basis as the difference between the groups and p values in the secondary outcomes (FAOS, VAS, RAND-36, ROM) where applicable. Categorical variables (occurrence of treatment-related adverse events and non-union) are analyzed with χ2 test or Fisher’s exact test and Wilson’s estimate for the CI of the absolute risk difference.

Adverse events (complications and harms) will be reported descriptively. If the number of events is large enough, an analysis between study arms will be performed.

The baseline characteristics of the participants will be summarized by group, reported as a mean (SD) or median (25th–75th percentiles) for continuous variables and count (per cent) for categorical variables.

Copyright and License information:  ©2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A